Cellular Adhesion Affecting Or Cell Adhesion Molecule (cam) Affecting Or Utilizing Patents (Class 514/19.1)
-
Patent number: 8329639Abstract: Provided herein are liposomal glycolipopeptidic vaccine formulations comprising an adjuvant and an immunogen for immunotherapy and/or treatment of cancer.Type: GrantFiled: July 19, 2012Date of Patent: December 11, 2012Assignee: Oncothyreon Inc.Inventors: Scott Peterson, Linda Pestano, Jeffrey Millard, Diana F. Hausman, Sandy Koppenol, Robert Kirkman
-
Publication number: 20120302506Abstract: The present invention provides maspin-related compositions and methods of use thereof. In particular, the present invention provides maspin-related compositions, and methods or use thereof, for the promotion of cell adhesion.Type: ApplicationFiled: May 23, 2012Publication date: November 29, 2012Inventor: Ming Zhang
-
Patent number: 8299030Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: August 8, 2011Date of Patent: October 30, 2012Assignee: GE Healthcare LimitedInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Publication number: 20120202748Abstract: The present invention relates to a bio-adhesive derived from mussel. In particular, it relates to a recombinant protein fp(foot protein)-131 that is a hybrid of fp-3 variant A and fp-1. According to the present invention, the recombinant protein with adhesive activity can be economically produced in large scale to be used in place of chemical adhesives.Type: ApplicationFiled: February 7, 2012Publication date: August 9, 2012Applicant: POSTECH ACADEMY-INDUSTRY FOUNDATIONInventors: Hyung Joon CHA, Dong Gyun KANG, Young Hoon SONG, Yoo Seong CHOI, Seonghye LIM
-
Patent number: 8207119Abstract: An object is to find the minimum activity expression site of fibronectin, clarify the actions of this minimum unit in relation to opthalmological fields, and provide an opthalmological composition having this minimum unit as an effective component. This invention provides an opthalmological composition, in particular, a corneal disorder treatment agent containing the peptide, PHSRN (SEQ ID NO: 1) (Pro-His-Ser-Arg-Asn (SEQ ID NO: 1)), or Ac-Pro-His-Ser-Arg-Asn-NH2, which is a derivative thereof, or a salt thereof that is allowable as a medical drug as an effective component. The preferred dosage form is an ophthalmic formulation.Type: GrantFiled: September 15, 2009Date of Patent: June 26, 2012Assignee: Nihon Tenganyaku Kenkyusho Co., Ltd.Inventors: Teruo Nishida, Yorihisa Uetake, Hiroaki Iwata
-
Patent number: 8153593Abstract: Transglutaminase inhibitors and methods of use thereof are provided.Type: GrantFiled: August 4, 2009Date of Patent: April 10, 2012Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Chaitan Khosla, Richard Edward Watts
-
Publication number: 20120045487Abstract: A multiphasic microfiber for a three-dimensional tissue scaffold and/or cellular support is provided in one aspect that includes at least one biocompatible material. The multiphasic microfiber optionally has a first phase and at least one distinct additional phase and is formed by electrohydrodynamic jetting. Further, such microfibers optionally have one or more biofunctional agents, which may be surface-bound moieties provided in spatial patterns. Multiphasic microfibers formed in accordance with the disclosure may form, in some cases, three-dimensional fiber scaffolds with precisely engineered, micrometer-scaled patterns for cellular contact guidance, which may thus support and/or promote cellular growth, proliferation, differentiation, repair, and/or regeneration for tissue and bioengineering applications.Type: ApplicationFiled: April 29, 2010Publication date: February 23, 2012Applicant: The Regents of the University of MichiganInventors: Joerg Lahann, Srijanani Bhaskar, Suparna Mandal
-
Publication number: 20120016489Abstract: Implantable pliable bone blocks comprising a solid block of cortical bone characterized by a length, width and thickness, having a first and a second face on opposite sides of the block. The first and second faces have a plurality slot features. The angle of incidence of the slot features of the first face and the x-axis and the angle of incidence of the slot features of the second face and the x-axis (a2) are such that the slots would intersect if they were in the same plane. Methods are provided for making implantable pliable bone blocks.Type: ApplicationFiled: July 16, 2010Publication date: January 19, 2012Applicant: EBI, LLCInventor: Bradford J. COALE
-
Patent number: 8092818Abstract: According to an aspect of the present invention, medical devices are provided, which contain (a) a substrate and (b) a polymeric region disposed over the substrate which contains at least one block copolymer. The block copolymer, in turn, contains at least two polymer blocks which phase separate into two or more immiscible phase domains within the polymeric region. Moreover, a bioactive species is covalently attached to at least one of the polymer blocks. By attaching the bioactive species selectively to at least one polymer block, self-assembled clusters of the bioactive species are created as the blocks phase separate into immiscible phase domains.Type: GrantFiled: May 17, 2006Date of Patent: January 10, 2012Assignee: Boston Scientific Scimed, Inc.Inventors: Robert E. Richard, Michael N. Helmus
-
Patent number: 8084236Abstract: Methods and compositions for modifying glycans (e.g., glycans expressed on the surface of live cells or cell particles) are provided herein.Type: GrantFiled: June 4, 2007Date of Patent: December 27, 2011Inventor: Robert Sackstein
-
Patent number: 8076295Abstract: Disclosed herein are novel peptide amphiphile molecules and compositions discovered to possess improved solubility in aqueous buffers which, in turn, facilitates purification required for pharmaceutical applications, particularly for in vivo administration to human patients. In addition, gels of such peptide amphiphile compositions are shown herein to possess unexpectedly superior gelation kinetics and rheological properties, including an increased mechanical stiffness, which better mimics the mechanical properties of natural central nervous system tissues.Type: GrantFiled: April 16, 2008Date of Patent: December 13, 2011Assignee: Nanotope, Inc.Inventors: James F. Hulvat, Mustafa O. Guler
-
Patent number: 8076086Abstract: The invention provides isolated nucleic acids encoding a variety of proteins and nucleic acids having diagnostic, preventive, therapeutic, and other uses. These nucleic acids and proteins are useful for diagnosis, prevention, and therapy of a number of human and other animal disorders. The invention also provides antisense nucleic acid molecules, expression vectors containing the nucleic acid molecules of the invention, host cells into which the expression vectors have been introduced, and non-human transgenic animals in which a nucleic acid molecule of the invention has been introduced or disrupted. The invention still further provides isolated polypeptides, fusion polypeptides, antigenic peptides and antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided. The nucleic acids and polypeptides of the present invention are useful as modulating agents in regulating a variety of cellular processes.Type: GrantFiled: August 4, 2006Date of Patent: December 13, 2011Assignee: Millennium Pharmaceuticals, Inc.Inventors: Susan J. Kirst, Douglas A. Holtzman, Christopher C. Fraser, John D. Sharp, Thomas S. Barnes
-
Patent number: 8071549Abstract: The present invention relates to a compound comprising the third Immunoglobulin (Ig3) module, and/or the fourth Immunoglobulin (Ig4) module, and/or the fifth immunoglobulin (Ig5) module, and/or the first Fibronectin III (Fn3,1) module, and/or the second Fibronectin III (Fn3,2) module of neural cell adhesion molecule (NCAM), or a fragment, or a variant thereof, capable of interacting with an Fibroblast Growth Factor (FGF) receptor and/or Adenosine-Tri-Phosphate (ATP) and/or L1, and thereby the compounds are capable of inducing differentiation, modulating proliferation, stimulate regeneration, neuronal plasticity and/or survival of cells. Further, the present invention relates to a pharmaceutical composition comprising said compound, a process of producing a pharmaceutical composition and the use of said compound.Type: GrantFiled: May 4, 2009Date of Patent: December 6, 2011Inventors: Vladislav V Kiselyov, Galina Skladchikova, Vladimir Berezin, Elisabeth Bock
-
Publication number: 20110293722Abstract: A macroporous hydrogel sponge is provided selected from: (i) a synthetic polymer hydrogel sponge, and (ii) a synthetic polymer-polypeptide conjugate hydrogel sponge, the macroporous hydrogel sponge being at least 20% porous and having a pore diameter of 50-1000 ?m, wherein said synthetic polymer is crosslinked to an extent determined by effecting the crosslinkig of the synthetic polymer or synthetic polymer-polypeptide conjugate in the presence of at least about 30% by weight crosslinking agent.Type: ApplicationFiled: December 6, 2009Publication date: December 1, 2011Applicant: TECHION RESEARCH AND DEVELOPMENT FOUNDATION LTD.Inventors: Tamar Kaully, Shulamit Levenberg
-
Publication number: 20110275573Abstract: Provided is an adhesive for adhering tissues. The adhesive includes a scaffolding and one or more peptides or proteins capable of binding to cells of both the first and second tissues. In a embodiment, the proteins or peptides have an amino acid sequence that is a subsequence of a ficolin protein, for example, a human ficolin.Type: ApplicationFiled: November 3, 2009Publication date: November 10, 2011Applicant: METAMOREFIX LTD.Inventors: Mazal Dahan, Ascher Shmulewitz
-
Publication number: 20110256057Abstract: The present application is directed to radiolabeled cyclic polyazapeptides, pharmaceutical compositions comprising radiolabeled cyclic polyazapeptides, and methods of using the radiolabeled cyclic polyazapeptides. Such polyazapeptides can be used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: ApplicationFiled: May 23, 2011Publication date: October 20, 2011Applicant: SIEMENS MEDICAL SOLUTIONS USA, INC.Inventors: Hartmuth C. Kolb, Kai Chen, Joseph C. Walsh, Dhanalakshmi Kasi, Vani P. Mocharla, Gang Chen, Qianwa Liang, Tieming Zhao
-
Publication number: 20110257102Abstract: A method of inhibiting neoplastic, cancer, and/or tumorgenic cell proliferation, cell growth and motility in a subject includes administering to a cancer cell expressing Pro-PrP and FLNa a therapeutically effective amount of a Pro-PrP regulating agent.Type: ApplicationFiled: December 23, 2009Publication date: October 20, 2011Inventors: Man-Sun Sy, Wei Xin, Chaoyang Li, Shuiliang Yi, Shaoman Yin
-
Publication number: 20110245184Abstract: Compositions, articles, devices and methods for the treatment and/or prevention of adhesions in humans and non-human animals.Type: ApplicationFiled: December 22, 2008Publication date: October 6, 2011Applicant: BRADFORD JAMES DUFTInventor: Bradford James Duft
-
Patent number: 8003613Abstract: The C-terminal domain of focal adhesion kinase (FAK-CD) was isolated using a Baculoviral system. Using phage display techniques, a phage encoding a 12 amino-acid peptide (peptide 35) and AV3 that binds to FAK-CD were identified. The peptides were also conjugated to TAT-FITC to produce a fluorescently labeled chimeric molecule capable of penetrating cell membranes. Contacting various breast cancer cell lines with these molecule caused detachment, rounding, apoptosis and cell death. These effects were not observed in normal (non-cancerous) breast cells.Type: GrantFiled: November 17, 2004Date of Patent: August 23, 2011Assignee: University of Florida Research Foundation, Inc.Inventors: William G. Cance, Vita Golubovskaya, Elena V. Kurenova
-
Patent number: 7994134Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: April 15, 2009Date of Patent: August 9, 2011Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bård Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Patent number: 7981866Abstract: Disclosed herein are nucleic acid sequences that encode novel polypeptides. Also disclosed are polypeptides encoded by these nucleic acid sequences, and antibodies, which immunospecifically-bind to the polypeptide, as well as derivatives, variants, mutants, or fragments of the aforementioned polypeptide, polynucleotide, or antibody. The invention further discloses therapeutic, diagnostic and research methods for diagnosis, treatment, and prevention of disorders involving any one of these novel human nucleic acids and proteins.Type: GrantFiled: July 11, 2007Date of Patent: July 19, 2011Assignee: University of Medicine and Dentistry of New JerseyInventors: Jianjie Ma, Noah Weisleder, Chuanxi Cai
-
Publication number: 20110123526Abstract: This invention provides methods and compositions for preventing post-surgical adhesion formation based on use of an interleukin-16 (IL-16) antagonist, including an IL-16 antagonist peptide and/or an IL-16 antagonist antibody.Type: ApplicationFiled: April 16, 2009Publication date: May 26, 2011Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: William W. Cruikshank, David M. Center
-
Publication number: 20110126302Abstract: Methods and kits for the diagnosis of illnesses related to protocadherin 19 (PCDH 19) protein deficiency or altered PCDH 19 protein function, in particular EFMR (Epilepsy and Mental Retardation limited to Females) are provided, as well as methods and kits for the identification of a predisposition to such illnesses and methods of screening subjects to identify carriers of such illnesses and methods and kits for the therapeutic or prophylactic treatment of PCDH 19 deficiency or altered PCDH 19 protein function. Further, nucleotide and amino acid sequences corresponding to a complete PCDH19 open reading frame (ORF), mutant sequences encoding non-functional PCDH19 mRNA or altered PCDH19 mRN A are described along with transformed cells and non-human transgenic animals comprising wild-type or mutant PCDH19 ORF nucleotide sequences.Type: ApplicationFiled: January 5, 2009Publication date: May 26, 2011Inventors: Leanne Michelle Dibbens, Ingrid Eileen Scheffer, Samuel Frank Berkovic, John Charles Mulley, Jozef Gecz
-
Publication number: 20110117163Abstract: For an implantable device intended for use in the human body an in-vivo colonization with autologous cells is often desired. The devices, especially prosthetic devices like implant tissues, grafts, shunts, vessels, organs or a part of organs are commonly derived from animal or human origin and comprise a collagen-based tissue matrix. The invention proposes a coating deposited on a surface of the device and comprising the matrix protein CCN1 as an extracellular matrix-associated protein mediating cell adhesion or cell migration.Type: ApplicationFiled: July 8, 2008Publication date: May 19, 2011Inventors: Andres Hilfiker, Denise Hilfiker-Kleiner, Artur Lichtenberg
-
Publication number: 20110111035Abstract: The various embodiments provide a composition that provides local control over inflammation. The composition localizes the activities of the cytokine-neutralizing antibodies to the site of inflammation through covalent attachment to hydrophilic matrices. The various embodiments including a hydrophilic polymer, a ligand binding moiety covalently attached to the polymer, and optionally, a cellular adhesion peptide covalently attached to the polymer. The hydrophilic polymer may be a glycosaminoglycan such as hyaluronan. The cellular adhesion peptide may be a linear RGD peptide sequence covalently attached to the polymer. The ligand binding moiety may be a monoclonal antibody covalently attached to the polymer. The antibody may be selected from the group consisting of an anti-IL-1?, an anti-IL-6, an anti-TNF-?, and combinations thereof. The polymer functions as a substrate or matrix for cell migration and tissue regeneration.Type: ApplicationFiled: August 15, 2008Publication date: May 12, 2011Inventors: Newell R. Washburn, Sidi Ahmed Bencherif, Liang Tso Sun
-
Publication number: 20110097388Abstract: This invention relates to methods of expressing eukaryotic proteins in prokaryotic hosts, particularly eukaryotic proteins that require formation of disulfide bridges for biological activity. Various approaches are used including fusion to thioredoxin, cytoplasmic expression of disulfide isomerases, deficiencies in thioredoxin and/or glutathione reductases, deficiencies in proteases, and the like. The method is applicable to express monomeric and dimeric forms of the eukaryotic protein with biological activity such as monomeric and dimeric forms of a disintegrin or a disintegrin domain. Included are the vectors, host cells expressing the proteins, the expressed proteins and methods of using the proteins.Type: ApplicationFiled: July 6, 2010Publication date: April 28, 2011Inventors: RADU O. MINEA, FRANCIS S. MARKLAND, JR.
-
Publication number: 20110054347Abstract: Implantable devices comprise at least one or more targeting molecules that form a primary coating layer for selectively recruiting, isolating, activating, and/or eliminating any cells of interest, such as T cells, monocytes, and stem cells. The implantable devices can be utilized for selectively removing a particular subset of cells from bodily fluids of a patient. Various non-selective pharmaceutical agents and biological agents can be incorporated into the implantable devices so that cells of interest can be isolated for elimination or for activation/differentiation. Cell-type selectivity is conferred by the presence of cell-type-specific targeting molecules incorporated into the implantable device, preferably at the surface level to permit direct or indirect interaction between the cells of interest and targeting molecules of the implantable device. Related therapeutic methods for utilizing the implantable devices are also provided.Type: ApplicationFiled: January 31, 2007Publication date: March 3, 2011Applicant: BIOMED SOLUTIONS LLCInventors: Kendrick Goss, Carol Gebert
-
Patent number: 7897575Abstract: The invention relates to compositions and methods for treating or preventing vascular dementia in a mammal comprising mucosal administration of an amount of E-selectin polypeptide sufficient to induce bystander immune tolerance in the mammal. Another aspect of the invention relates to compositions useful for treating or preventing vascular dementia.Type: GrantFiled: February 28, 2008Date of Patent: March 1, 2011Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: John M. Hallenbeck, Hideaki Wakita
-
Bone graft and scaffolding materials immobilized with osteogenesis enhancing peptides on the surface
Patent number: 7897163Abstract: The present invention relates to a bone graft material and a scaffold for tissue engineering applications, which have an osteogenesis-promoting peptide immobilized on the surface. More particularly, the invention relates to a bone graft material and a scaffold for tissue engineering applications, which have a cell adhesion-inducing peptide and/or tissue growth factor-derived peptide immobilized on the surface. By the osteogenesis-promoting peptide immobilized on the surface, the inventive bone graft material and scaffold for tissue engineering applications can promote the transition, proliferation and differentiation of cells associated with regeneration, and eventually maximize the regeneration of tissue. Moreover, the peptide immobilized on the surface has low molecular weight, indicating a reduced risk of immune responses upon its application in the body, and can be present in a stable form within the body, thus showing lasting effects.Type: GrantFiled: March 18, 2005Date of Patent: March 1, 2011Assignee: Seoul National University Industry FoundationInventors: Yoon Jeong Park, Chong-Pyoung Chung, Seung Jin Lee, Sang Hoon Rhee -
Publication number: 20110034396Abstract: The present disclosure provides methods of use of saratin, including the prevention or mitigation of the development of adhesions, keloids and scars. The adhesions, keloids and scars can be due to surgery, such as plastic surgery or orthopedic surgery, or can be pre-existing scars. Adhesion, keloid and/or scar formation may also be prevented in surgical procedures utilizing shunts, implants or drainage devices, including surgical procedures to treat glaucoma.Type: ApplicationFiled: August 27, 2010Publication date: February 10, 2011Applicant: BioVascular, Inc.Inventor: Paul F. Glidden
-
Publication number: 20110014264Abstract: According to certain aspects of the invention, implantable or insertable medical devices are provided that contain one or more nanoporous regions, which may further comprise interconnected nanopores. Other aspects of the invention are directed to implantable or insertable medical devices that contain one or more nanostructured regions, which are formed by a variety of methods. Still other aspects of the invention are directed to implantable or insertable medical devices having nanotextured surface regions, in which cell-adhesion-promoting biomolecules (e.g., glycosaminoglycans, proteoglycans, cell adhesion peptides, and adhesive proteins) are provided on, within or beneath the nanotextured surface regions.Type: ApplicationFiled: September 23, 2010Publication date: January 20, 2011Applicant: BOSTON SCIENTIFIC SCIMED, INC.Inventors: Michael N. Helmus, Yixin Xu, Shrirang V. Ranade
-
Publication number: 20100323969Abstract: The present invention relates to derivatives of compounds which bind selectively to the adhesion molecule human P-selectin, and particularly to such derivatives which comprise a peptide moiety or a functional equivalent of said peptide moiety and are represented by X(Ax)mA3A1A2A1Y. In addition, the invention relates to methods for preparing such compounds, to the use of such compounds in therapeutic or diagnostic methods and in pharmaceutical compositions, to binding molecules binding to said compounds and to a method for determining whether a compound is capable of binding to P-selectin.Type: ApplicationFiled: March 16, 2010Publication date: December 23, 2010Applicant: ASTELLAS PHARMA EUROPE B.V.Inventors: Chantal Catharina Maria Appeldoorn, Erik Anna Leonardus Biessen, Thomas Jacobus Maria Molenaar, Johan Kuiper, Theodorus Josephus Cornelis Van Berkel
-
Publication number: 20100310458Abstract: The invention relates to new uses of soluble CEACAM6 or CEACAM8, or substances that are specific to soluble CEACAM8. Another object of the invention concerns the use of CEACAM1-specific and/or CEACAM6-specific compounds for apoptosis prevention in-vitro. The invention also relates to a method for screening compounds, which prevent apoptosis and a method for preventing apoptosis in human granulocytes.Type: ApplicationFiled: September 26, 2008Publication date: December 9, 2010Applicant: CHARITÉ- UNIVERSITÄTSMEDIZIN BERLINéInventor: Bernhard Singer
-
Publication number: 20100303819Abstract: The present invention relates generally to a novel lectin and to derivatives, homologues, analogues, chemical equivalents and mimetics thereof and, more particularly, to a novel type I C-type lectin, herein referred to as “DCL-1”. In particular, the present invention relates to the use of DCL-1 in therapeutic, prophylactic and diagnostic applications.Type: ApplicationFiled: May 10, 2010Publication date: December 2, 2010Applicant: THE CORPORATION OF THE TRUSTEES OF THE ORDER OF THE SISTERS OF MERCY IN QUEENSLANDInventors: DEREK NIGEL JOHN HART, Masato Kato
-
Publication number: 20100247652Abstract: The present invention relates to methods for the treatment of hepatic disorders in a subject in need thereof. More specifically, the methods of the invention are based on the administration, preferably, systemic administration, of a therapeutically effective amount of at least one biocompatible alginate biomaterial, any modification thereof and any combination thereof. The invention further provides methods for sustaining serum albumin levels, and/or reducing serum AST and ALT, in subjects suffering from hepatic disorder. Still further, the invention provides methods for reducing apoptosis and inducing cell proliferation in a damaged liver tissue of a subject suffering of hepatic disorder, using the alginate biomaterial described by the invention.Type: ApplicationFiled: November 27, 2008Publication date: September 30, 2010Applicants: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD., BEN-GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITYInventors: Yaron Ilan, Gadi Lalazar, Eyal Shteyer, Ami Ben-Yaakov, Smadar Cohen, Tsiona Elkayam